The BioWorld Insider Podcast – Détails, épisodes et analyse
Détails du podcast
Informations techniques et générales issues du flux RSS du podcast.
Classements récents
Dernières positions dans les classements Apple Podcasts et Spotify.
Apple Podcasts
🇬🇧 Grande Bretagne - lifeSciences
23/05/2026#96🇬🇧 Grande Bretagne - lifeSciences
22/05/2026#80🇬🇧 Grande Bretagne - lifeSciences
21/05/2026#64🇬🇧 Grande Bretagne - lifeSciences
20/05/2026#50🇬🇧 Grande Bretagne - lifeSciences
19/05/2026#33🇺🇸 États-Unis - lifeSciences
19/04/2026#94🇬🇧 Grande Bretagne - lifeSciences
05/01/2026#99🇬🇧 Grande Bretagne - lifeSciences
04/01/2026#93🇬🇧 Grande Bretagne - lifeSciences
03/01/2026#72🇬🇧 Grande Bretagne - lifeSciences
02/01/2026#66
Spotify
Aucun classement récent disponible
Liens partagés entre épisodes et podcasts
Liens présents dans les descriptions d'épisodes et autres podcasts les utilisant également.
See all- https://biofuture.com/
6 partages
- https://www.bioworld.com/aging
2 partages
Qualité et score du flux RSS
Évaluation technique de la qualité et de la structure du flux RSS.
See allScore global : 52%
Historique des publications
Répartition mensuelle des publications d'épisodes au fil des années.
Capricor's CEO pursues a BLA and talks rare disease
Saison 1 · Épisode 42
vendredi 27 septembre 2024 • Durée 15:50
Capricor Therapeutics Inc. just wrapped up a visit with the U.S. FDA and is prepping to file a BLA in October for its Duchenne muscular dystrophy treatment. Linda Marbán, Capricor's CEO, is the guest on the newest BioWorld Insider podcast and she talks about deramiocel (CAP-1002), the company's allogeneic cardiac-derived cell therapy, for treating the rare disease and how the FDA has made strong efforts in helping lay the groundwork for deramiocel. Marbán has been working on the Duchenne treatment for many years and she has strong insights into how to tackle a rare disease development program and how the FDA has changed its ways over time to help out. She has been in the biopharma space for more than 20 years and also is a co-founder of Capricor.
The first half of 2024 was strong as M&As and financings dominate
Saison 1 · Épisode 41
vendredi 26 juillet 2024 • Durée 18:01
Karen Carey, BioWorld managing editor and chief analyst, takes a look at the numbers from the first half of 2024. She finds the first six months to be healthy for the biopharma market while the rest of the year is populated with question marks that include the U.S. presidential election and potential interest rate cuts.
The struggle is real: The first half of 2023 was an uphill climb
Saison 1 · Épisode 30
mercredi 16 août 2023 • Durée 25:47
Guests Karen Carey, BioWorld's managing editor, and Mike Ward, Clarivate's global head of Life Sciences and Healthcare Thought Leadership, discuss the deals, financing and M&A landscape for the first half of 2023 and how U.K. biopharmas are faring post Brexit.
The biosimilars challenge to Humira revs up
Saison 1 · Épisode 29
jeudi 20 juillet 2023 • Durée 17:06
Guests BioWorld Regulatory Editor Mari Serebrov and Tom Newcomer, Samsung Bioepis vice president and head of U.S. market access, discuss the launch of biosimilars that are taking on a blockbuster.
Preventing opioid overdoses with a smart patch
lundi 5 juin 2023 • Durée 23:20
Brad Holden, CEO of Resilient Lifescience, explains how the device works for overdoses as well as other potential applications for this new technology.
Better times ahead for the biopharma sector? Could be, the new numbers say
Saison 1 · Épisode 27
lundi 24 avril 2023 • Durée 28:02
Karen Carey, BioWorld's managing editor and senior data analyst, and Tim Shannon, a general partner at Canaan, break down the numbers from first quarter of 2023.
Hosted on Acast. See acast.com/privacy for more information.
Radiopharmaceuticals: The next big disrupter?
Saison 1 · Épisode 26
mercredi 5 avril 2023 • Durée 13:58
BioWorld Staff Writer Tamra Sami talks about the science behind radiopharmaceuticals, the supply chain vulnerabilities, the regulatory landscape, the patient journey and therapies in the pipeline.
Hosted on Acast. See acast.com/privacy for more information.
Cambrian carves out a new niche as it works to keep people from getting sick
Saison 1 · Épisode 25
mardi 21 février 2023 • Durée 28:06
James Peyer, the CEO of Cambrian Biopharma Inc., talks about anti-aging therapies, a business model that fits the new field of geroscience.
Hosted on Acast. See acast.com/privacy for more information.
Rethinking obesity: Fitness may be more directly linked to health than weight
Saison 1 · Épisode 24
lundi 30 janvier 2023 • Durée 21:23
BioWorld Science Managing Editor Anette Breindl discusses her new analysis of multiple studies related to weight loss, metabolic health and fitness that in many ways go against mainstream theories about obesity.
Hosted on Acast. See acast.com/privacy for more information.
Looking ahead to 2023: CEOs contemplate the new normal
Saison 1 · Épisode 23
lundi 5 décembre 2022 • Durée 24:55
Guests Karen Zaderej, CEO of Axogen Inc., Sean Bohen, CEO of Olema Oncology Inc., Rob Ross, the CEO of Surface Oncology Inc., and Rob Etherington, the CEO of Clene Nanomedicine Inc., speak about adapting their companies to the market's new realities.
Hosted on Acast. See acast.com/privacy for more information.
Podcasts Similaires Basées sur le Contenu
